Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Mease Philip; Coates Laura C.; Helliwell Philip S.; Stanislavchuk Mykola; Rychlewska-Hanczewska Anna; Dudek Anna; Abi-Saab Walid; Tasset Chantal; Meuleners Luc; Harrison Pille; Besuyen Robin; Van der Aa Annegret; Mozaffarian Neelufar; Greer Joy M.; Kunder Rebecca; Van den Bosch Filip; Gladman Dafna D.

首页> 外文期刊>The Lancet >Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

【24h】

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

机译：菲尔替尼（一种有选择的Janus激酶1抑制剂）的菌株和安全性在活性银屑病关节炎（赤道）中的抑制剂（赤道）：由随机，安慰剂控制，第2阶段试验结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background The Janus kinase 1 (JAK1) pathway has been implicated in the pathogenesis of psoriatic arthritis. We aimed to investigate the efficacy and safety of filgotinib, a selective JAK1 inhibitor, for the treatment of psoriatic arthritis.

机译：背景技术Janus激酶1（JAK1）途径涉及银屑病关节炎的发病机制。我们旨在探讨菲尔替尼，选择性JAK1抑制剂的疗效和安全性，用于治疗银屑病关节炎。

著录项

来源
《The Lancet》 |2018年第10162期|共11页
作者
Mease Philip; Coates Laura C.; Helliwell Philip S.; Stanislavchuk Mykola; Rychlewska-Hanczewska Anna; Dudek Anna; Abi-Saab Walid; Tasset Chantal; Meuleners Luc; Harrison Pille; Besuyen Robin; Van der Aa Annegret; Mozaffarian Neelufar; Greer Joy M.; Kunder Rebecca; Van den Bosch Filip; Gladman Dafna D.;
展开▼
作者单位

Swedish Providence St Joseph Hlth Syst Seattle WA 98122 USA;

Univ Oxford Nuffield Dept Orthopaed Rheumatol &

Musculoskelet Oxford England;

Leeds Inst Rheumat &

Musculoskeletal Med Leeds W Yorkshire England;

Natl Pirogov Mem Med Univ Vinnytsya Ukraine;

Ai Ctr Med Poznan Poland;

Ctr Med AMED Warsaw Poland;

Galapagos NV Mechelen Belgium;

Galapagos NV Mechelen Belgium;

Galapagos NV Mechelen Belgium;

Galapagos NV Mechelen Belgium;

Galapagos BV Leiden Netherlands;

Galapagos NV Mechelen Belgium;

Gilead Sci Foster City CA USA;

Gilead Sci Foster City CA USA;

Gilead Sci Foster City CA USA;

Ghent Univ Hosp Ghent Belgium;

Univ Toronto Toronto ON Canada;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial [J] . Mease Philip, Coates Laura C., Helliwell Philip S., The Lancet . 2018,第10162期

机译：菲尔替尼（一种有选择的Janus激酶1抑制剂）的菌株和安全性在活性银屑病关节炎（赤道）中的抑制剂（赤道）：由随机，安慰剂控制，第2阶段试验结果
2. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study [J] . Takeuchi Tsutomu, Tanaka Yoshiya, Iwasaki Manabu, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2016,第6期

机译：口服Janus激酶抑制剂培非替尼（ASP015K）单一疗法在日本中重度类风湿关节炎患者中的疗效和安全性：一项为期12周，随机，双盲，安慰剂对照的IIb期研究
3. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. [J] . Coombs JH, Bloom BJ, Breedveld F Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2010,第2期

机译：使用口服活性Janus激酶（JAK）抑制剂CP-690,550治疗的类风湿关节炎患者的疼痛，身体功能和健康状况得到改善：这是一项随机，双盲，安慰剂对照试验的结果。
4. Synbiotic Therapy Significantly Reduces Molecular Markers of Inflammation and Clinical Scores in Patients with Active Ulcerative Colitis; A Randomised Controlled Trial [C] . Controlled Release Society annual meeting . 2004

机译：同步治疗显着减少了活性溃疡性结肠炎患者的炎症和临床评分的分子标记;随机对照试验
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Extended report: Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week randomised double-blind placebo-controlled phase IIb study [O] . Tsutomu Takeuchi, Yoshiya Tanaka, Manabu Iwasaki, -1

机译：扩展报告：口服Janus激酶抑制剂培非替尼（ASP015K）单一疗法在日本中重度类风湿关节炎患者中的疗效和安全性：一项为期12周随机双盲安慰剂对照的IIb期研究
7. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial [O] . Philip Mease, Laura C Coates, Philip S Helliwell, 2018

机译：菲尔替尼（一种有选择的Janus激酶1抑制剂）的菌株和安全性在活性银屑病关节炎（赤道）中的抑制剂（赤道）：由随机，安慰剂控制，第2阶段试验结果

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

摘要

著录项

相似文献

相关主题

期刊订阅